

Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

ICD-10 D46: Myelodysplastic syndrome

Incidence and Mortality

Year of diagnosis	1998-2020
Patients	3,247
Diseases	3,253
Creation date	12/21/2021
Database export	12/20/2021
Population	4.95 m



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

https://www.tumorregister-muenchen.de/en/facts/base/bD46__E-ICD-10-D46-Myelodysplastic-syndrome-incidence-and-mortality.pdf

Index of figures and tables

Fig./Tbl.		Page
1	Annual cases, DCO, mult. malignancies, follow-up / yr	4
2	Incidence by year of diagnosis	7
3	Age distribution parameters by year of diagnosis	8
4	Age distribution by 5-year age group and sex	11
5	Age-specific incidence, DCO rate	12
6	Age distribution and age-specific incidence (chart)	13
6a	Age-specific incidence internationally (chart)	14
7	Standardized incidence ratio of further malignancies	15
8a	Map of cancer incidence (BRD-S) by county (chart)	17
8b	Standardized incidence ratio (SIR) by county (chart)	18
9a	Pts incident cohorts and mortality / yr	19
9b	Incidence and mortality by year of diagnosis	20
9c	Cancer-related deaths, death certification available / yr	21
10	Medians of age at death / yr	22
11	Mortality by year of death	24
12	Distribution of age at death	26
13	Age-specific mortality	27
14	Further malignancies in deaths	28
15	Age-specific mortality (first primaries)	30
16	Age-specific mortality (single primaries)	31
17	Age distribution and age-specific mortality (chart)	32
18a	Map of cancer mortality (BRD-S) by county (chart)	33
18b	Standardized mortality ratio (SMR) by county (chart)	34

**Global Statements about the statistics on the Internet –
Baseline Statistics** (grey button ) , **Survival** (red button )

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.69 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases^{###} are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, December 2021

- [#] Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.65 million to 4.10 in 2002, and to 4.69 million in 2007).
- ^{##} Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- ^{###} DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate.

ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
D46.-	Myelodysplastic syndromes
D46.0	Refractory anaemia without ring sideroblasts, so stated
D46.1	Refractory anaemia with ring sideroblasts
D46.2	Refractory anaemia with excess of blasts [RAEB]
D46.4	Refractory anaemia, unspecified
D46.5	Refractory anaemia with multi-lineage dysplasia
D46.6	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.7	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified

INCIDENCE

Table 1

Cases by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (ALL PATIENTS) (incl. DCO)

Year of diagnosis	All cases n	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	51	27	52.9	15.7	14.2	96.1	100.0
1999	57	27	47.4	15.7	14.3	96.5	100.0
2000	68	41	60.3	17.0	14.4	95.6	100.0
2001	60	37	61.7	15.7	14.6	95.0	100.0
2002	110	60	54.5	16.8	14.5	97.3	100.0 #
2003	99	56	56.6	18.0	14.6	96.0	99.0
2004	111	68	61.3	19.4	14.6	93.7	99.1
2005	143	94	65.7	19.3	14.9	96.5	98.6
2006	150	84	56.0	20.7	15.2	90.0	96.0
2007	195	98	50.3	20.7	15.4	89.2	96.4 #
2008	205	98	47.8	21.1	15.3	91.7	98.5
2009	203	83	40.9	21.6	15.4	86.2	100.0
2010	206	91	44.2	22.3	14.5	89.3	99.5
2011	246	110	44.7	23.3	14.4	90.7	100.0
2012	211	108	51.2	24.1	13.5	91.9	99.5
2013	221	92	41.6	24.2	13.2	86.4	100.0
2014	175	94	53.7	24.6	12.7	93.7	98.9
2015	179	100	55.9	25.1	11.7	91.1	99.4
2016	198	118	59.6	24.9	11.8	87.9	99.0
2017	169	99	58.6	25.5	10.9	85.2	99.4
2018	111	51	45.9	26.1	13.4	74.8	99.1
2019	45	2	4.4	26.6	14.3	60.0	100.0
2020	40	3	7.5	26.7	10.3	52.5	100.0 ##
1998-2020	3253	1641	50.4	26.7	14.2	89.5	99.1

3,253 cases diagnosed 1998-2020 are related to a total of 3,247 patients. Currently, in 1,381 (42.5 %) of these 3,247 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 1,048 / 258 / 75 (32.3 % / 7.9 % / 2.3 %) patients exist having 2 / 3 / 4+ malignancies.

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2018, a subgroup of 111 cases has been diagnosed, of which 26.1 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 13.4 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1a

Cases by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (MALES) (incl. DCO)

Year of diagnosis	Males n	Males %	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	17	33.3	8	47.1	17.6	16.3	88.2	100.0
1999	29	50.9	13	44.8	17.4	16.4	93.1	100.0
2000	37	54.4	18	48.6	18.1	16.6	91.9	100.0
2001	21	35.0	14	66.7	17.3	16.8	95.2	100.0
2002	61	55.5	28	45.9	18.2	16.8	98.4	100.0 #
2003	51	51.5	27	52.9	17.1	16.9	96.1	98.0
2004	66	59.5	34	51.5	18.8	16.7	93.9	98.5
2005	70	49.0	42	60.0	18.8	17.2	98.6	100.0
2006	87	58.0	44	50.6	20.3	17.4	90.8	95.4
2007	107	54.9	47	43.9	21.2	17.6	85.0	96.3 #
2008	93	45.4	40	43.0	21.9	17.4	92.5	96.8
2009	105	51.7	38	36.2	22.4	17.3	82.9	100.0
2010	116	56.3	49	42.2	23.6	16.3	89.7	100.0
2011	120	48.8	46	38.3	24.8	16.2	90.8	100.0
2012	111	52.6	50	45.0	25.8	15.4	91.9	99.1
2013	123	55.7	49	39.8	26.1	14.9	87.8	100.0
2014	97	55.4	47	48.5	26.4	14.3	91.8	97.9
2015	87	48.6	42	48.3	26.8	13.8	87.4	100.0
2016	116	58.6	63	54.3	26.7	14.4	86.2	99.1
2017	100	59.2	50	50.0	27.3	12.9	84.0	99.0
2018	68	61.3	30	44.1	28.1	15.2	72.1	98.5
2019	25	55.6	1	4.0	28.5	16.3	60.0	100.0
2020	25	62.5	2	8.0	28.7	8.3	48.0	100.0 ##
1998–2020	1732	53.2	782	45.2	28.7	16.3	88.2	98.9

1,732 cases diagnosed 1998-2020 are related to a total of 1,727 patients. Currently, in 807 (46.7 %) of these 1,727 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 602 / 149 / 56 (34.9 % / 8.6 % / 3.2 %) patients exist having 2 / 3 / 4+ malignancies.

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2018, a subgroup of 68 cases has been diagnosed, of which 28.1 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 15.2 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1b

Cases by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (FEMALES) (incl. DCO)

Year of diagnosis	Females n	Females %	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	34	66.7	19	55.9	14.7	11.9	100.0	100.0
1999	28	49.1	14	50.0	14.5	12.0	100.0	100.0
2000	31	45.6	23	74.2	16.1	12.1	100.0	100.0
2001	39	65.0	23	59.0	14.4	12.2	94.9	100.0
2002	49	44.5	32	65.3	15.5	11.8	95.9	100.0 #
2003	48	48.5	29	60.4	18.8	12.0	95.8	100.0
2004	45	40.5	34	75.6	20.1	12.1	93.3	100.0
2005	73	51.0	52	71.2	19.9	12.3	94.5	97.3
2006	63	42.0	40	63.5	21.2	12.8	88.9	96.8
2007	88	45.1	51	58.0	20.1	13.0	94.3	96.6 #
2008	112	54.6	58	51.8	20.2	13.0	91.1	100.0
2009	98	48.3	45	45.9	20.8	13.1	89.8	100.0
2010	90	43.7	42	46.7	20.9	12.4	88.9	98.9
2011	126	51.2	64	50.8	21.6	12.3	90.5	100.0
2012	100	47.4	58	58.0	22.3	11.2	92.0	100.0
2013	98	44.3	43	43.9	22.2	11.1	84.7	100.0
2014	78	44.6	47	60.3	22.7	10.7	96.2	100.0
2015	92	51.4	58	63.0	23.2	9.1	94.6	98.9
2016	82	41.4	55	67.1	22.9	7.9	90.2	98.8
2017	69	40.8	49	71.0	23.6	7.9	87.0	100.0
2018	43	38.7	21	48.8	24.0	10.8	79.1	100.0
2019	20	44.4	1	5.0	24.4	11.4	60.0	100.0
2020	15	37.5	1	6.7	24.5	13.3	60.0	100.0 ##
1998-2020	1521	46.8	859	56.5	24.5	11.9	90.9	99.3

1,521 cases diagnosed 1998-2020 are related to a total of 1,520 patients. Currently, in 574 (37.8 %) of these 1,520 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 446 / 109 / 19 (29.3 % / 7.2 % / 1.3 %) patients exist having 2 / 3 / 4+ malignancies.

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2018, a subgroup of 43 cases has been diagnosed, of which 24.0 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 10.8 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 2

Incidence measures by year of diagnosis including DCO cases
(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,
and from 4.10 to 4.94 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	17	34	1.5	2.9	1.2	1.1	1.5	1.7	1.9	2.4
1999	29	28	2.6	2.4	1.7	0.6	2.5	1.1	3.8	1.7
2000	37	31	3.2	2.6	1.9	0.8	2.9	1.3	4.1	1.8
2001	21	39	1.8	3.2	0.9	1.1	1.6	1.7	2.5	2.3
2002	61	49	3.3	2.5	1.6	0.7	2.7	1.3	4.0	1.9
2003	51	48	2.7	2.4	1.4	0.7	2.2	1.2	3.3	1.7
2004	66	45	3.5	2.3	1.7	0.7	2.9	1.1	4.1	1.7
2005	70	73	3.7	3.7	1.6	1.2	2.8	1.8	4.3	2.5
2006	87	63	4.5	3.1	2.3	0.9	3.6	1.5	4.9	2.2
2007	107	88	4.8	3.8	2.6	1.3	3.8	2.0	5.1	2.8
2008	93	112	4.2	4.8	2.0	1.8	3.0	2.6	4.3	3.4
2009	105	98	4.7	4.2	2.3	1.5	3.4	2.3	4.7	3.2
2010	116	90	5.1	3.8	2.2	1.1	3.6	1.8	5.2	2.7
2011	120	126	5.4	5.4	2.2	1.6	3.5	2.6	5.2	3.6
2012	111	100	4.9	4.2	2.2	1.4	3.4	2.0	4.8	2.8
2013	123	98	5.3	4.1	2.3	1.4	3.5	2.1	5.1	2.9
2014	97	78	4.2	3.2	1.7	0.9	2.7	1.4	3.8	2.1
2015	87	92	3.7	3.8	1.5	1.0	2.4	1.7	3.3	2.4
2016	116	82	4.8	3.3	1.6	0.9	2.8	1.5	4.2	2.2
2017	100	69	4.1	2.8	1.5	0.7	2.5	1.2	3.6	1.8
2018	68	43	2.8	1.7	1.0	0.4	1.6	0.7	2.4	1.1
2019	25	20	1.0	0.8	0.4	0.3	0.6	0.4	0.9	0.6
2020	25	15	1.0	0.6	0.4	0.2	0.7	0.3	0.9	0.4
1998-2020	1732	1521	3.7	3.2	1.7	1.0	2.6	1.5	3.7	2.2

The computation of the incidence measures includes all cancers, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (ALL PATIENTS)
(incl. DCO)

Year of diagnosis	Cases n	Std.		Median						
		Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	51	73.7	16.4	4.5	93.4	62.4	67.2	74.2	84.8	87.9
1999	57	76.4	16.0	1.7	94.6	64.6	73.4	80.9	85.0	89.4
2000	68	75.2	14.4	10.2	101	58.3	67.1	76.7	87.1	90.9
2001	60	76.4	13.1	31.7	96.0	61.2	71.3	78.6	85.1	90.5
2002	110	77.2	10.3	41.0	97.4	65.0	72.9	77.6	83.2	90.1
2003	99	76.1	13.6	12.2	93.9	63.1	69.0	78.4	84.5	89.4
2004	111	76.9	12.2	12.0	103	63.6	69.5	78.5	85.4	90.2
2005	143	77.3	12.0	6.0	97.1	65.2	70.6	80.4	84.6	90.0
2006	150	74.9	14.2	4.5	96.5	59.0	68.8	78.6	84.7	88.9
2007	195	74.9	17.8	3.0	100	58.5	69.2	78.3	85.6	89.9
2008	205	74.9	15.4	3.9	99.5	60.3	69.4	77.9	84.8	88.9
2009	203	73.8	14.7	2.6	100	58.1	67.0	77.3	83.4	88.1
2010	206	77.1	13.2	3.7	98.9	65.5	72.1	79.4	85.1	89.0
2011	246	76.9	12.5	3.7	95.8	64.8	72.0	78.8	85.4	88.5
2012	211	76.4	15.5	4.6	99.0	62.7	71.1	79.8	86.6	90.1
2013	221	75.2	14.5	7.6	97.5	62.5	71.0	77.4	83.7	88.2
2014	175	77.7	13.3	3.9	99.3	67.1	73.3	79.0	86.0	90.0
2015	179	78.3	11.6	5.2	96.0	63.7	73.1	79.9	86.2	90.2
2016	198	79.7	9.4	35.7	96.7	66.0	75.8	81.0	86.7	90.4
2017	169	78.1	12.2	25.8	98.5	61.3	72.2	79.8	85.6	91.6
2018	111	79.4	9.0	49.8	96.1	67.1	74.5	81.0	85.8	90.3
2019	45	73.7	11.7	28.4	91.2	59.4	70.2	75.8	80.4	85.9
2020	40	75.0	9.7	44.8	91.2	62.5	70.5	76.2	81.3	86.2
1998-2020	3253	76.5	13.5	1.7	103	62.8	71.1	78.8	85.0	89.6

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of diagnosis	Cases n	Std.		Median						
		Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	17	66.2	23.4	4.5	90.1	11.6	63.8	72.2	78.3	86.2
1999	29	70.7	19.7	1.7	90.6	47.2	67.7	74.2	81.4	85.0
2000	37	71.0	15.4	10.2	93.8	55.2	62.5	74.0	80.5	88.5
2001	21	74.3	9.6	49.9	89.1	62.1	70.7	76.7	80.8	82.7
2002	61	75.3	11.0	41.0	92.1	62.8	69.9	76.4	82.6	86.8
2003	51	73.4	15.0	12.2	93.9	61.8	65.7	76.2	82.5	87.1
2004	66	76.4	10.1	54.9	93.7	62.5	68.6	77.4	85.4	89.2
2005	70	76.0	10.1	27.1	95.6	66.0	71.0	77.7	81.4	86.0
2006	87	72.2	14.3	4.5	96.5	56.4	63.1	72.8	82.4	88.8
2007	107	72.1	19.6	3.0	100	50.3	68.5	76.5	84.1	87.8
2008	93	72.7	14.2	14.0	94.6	55.7	67.9	74.7	82.2	87.2
2009	105	72.4	14.1	2.6	92.5	60.3	66.9	73.6	82.1	86.1
2010	116	76.3	14.0	3.7	98.9	63.2	70.6	79.2	84.9	88.8
2011	120	75.2	12.1	3.7	89.0	66.1	71.4	76.7	82.5	85.6
2012	111	74.9	15.6	10.0	96.8	62.5	68.1	77.4	84.7	89.7
2013	123	74.0	15.2	7.6	93.0	62.1	70.8	76.5	83.3	85.8
2014	97	75.8	14.5	3.9	99.3	64.7	71.2	78.4	82.9	89.3
2015	87	76.7	12.2	5.2	93.7	63.7	71.9	77.8	85.1	89.2
2016	116	79.5	9.8	35.7	96.7	66.0	75.7	81.4	86.2	90.1
2017	100	77.0	11.7	33.1	97.5	60.3	71.0	79.2	85.1	90.2
2018	68	78.4	9.5	49.8	94.8	66.1	72.3	79.5	85.3	89.5
2019	25	74.1	8.9	47.0	87.9	61.8	71.2	75.8	78.3	83.5
2020	25	73.9	9.2	49.8	88.3	61.4	68.3	74.6	81.3	83.9
1998-2020	1732	74.9	13.8	1.7	100	61.5	69.6	77.3	83.4	88.1

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)
(incl. DCO)

Year of diagnosis	Cases n	Std.		Median						
		Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	34	77.4	10.1	56.3	93.4	65.5	67.8	79.1	84.9	89.6
1999	28	82.2	7.8	64.6	94.6	66.4	78.4	83.7	87.2	92.3
2000	31	80.4	11.2	53.3	101	64.9	74.7	80.7	89.2	91.2
2001	39	77.6	14.6	31.7	96.0	61.0	72.9	81.0	88.4	90.8
2002	49	79.5	8.8	62.8	97.4	66.2	74.2	78.2	85.0	92.4
2003	48	78.9	11.4	39.6	92.7	66.4	76.3	82.0	86.5	89.7
2004	45	77.7	14.9	12.0	103	64.1	75.1	80.1	86.4	90.6
2005	73	78.6	13.5	6.0	97.1	64.2	70.3	82.9	85.5	92.5
2006	63	78.5	13.3	12.5	92.4	66.9	71.7	82.2	86.2	90.2
2007	88	78.2	14.6	7.4	98.1	62.9	73.2	81.3	87.6	92.4
2008	112	76.8	16.3	3.9	99.5	63.1	72.3	80.4	86.3	90.7
2009	98	75.2	15.3	12.9	100	57.4	69.1	78.6	85.1	88.9
2010	90	78.2	12.1	13.3	93.4	68.8	72.9	80.8	86.2	89.2
2011	126	78.5	12.7	10.1	95.8	63.0	72.9	81.8	87.4	90.3
2012	100	78.1	15.3	4.6	99.0	63.1	72.0	81.7	87.9	90.3
2013	98	76.7	13.6	11.3	97.5	62.7	72.7	78.6	86.4	91.1
2014	78	80.1	11.3	12.6	97.2	70.2	74.8	79.6	87.8	91.9
2015	92	79.7	10.8	43.6	96.0	66.8	75.5	80.7	87.4	90.4
2016	82	80.0	8.8	52.6	96.4	68.6	76.3	80.4	86.8	90.4
2017	69	79.7	12.7	25.8	98.5	67.6	75.1	81.5	86.4	93.4
2018	43	81.1	7.8	60.4	96.1	69.3	77.3	81.6	85.9	90.7
2019	20	73.3	14.8	28.4	91.2	53.2	69.0	75.9	82.3	87.7
2020	15	77.0	10.6	44.8	91.2	71.8	74.3	76.4	84.6	86.4
1998-2020	1521	78.4	13.0	3.9	103	64.6	73.0	80.7	86.7	90.7

Table 4

Age distribution by 5-year age group and sex for period 2007–2020
(incl. DCO)

Age at diagnosis Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0–4	7	0.3	0.3	5	0.4	0.4	2	0.2	0.2
5–9	6	0.2	0.5	4	0.3	0.7	2	0.2	0.4
10–14	20	0.8	1.4	12	0.9	1.6	8	0.7	1.1
15–19	7	0.3	1.7	5	0.4	2.0	2	0.2	1.3
20–24	0	0.0	1.7			2.0			1.3
25–29	6	0.2	1.9	2	0.2	2.2	4	0.4	1.6
30–34	3	0.1	2.0	3	0.2	2.4			1.6
35–39	9	0.4	2.4	2	0.2	2.6	7	0.6	2.3
40–44	14	0.6	3.0	9	0.7	3.2	5	0.5	2.7
45–49	20	0.8	3.8	14	1.1	4.3	6	0.5	3.2
50–54	26	1.1	4.9	14	1.1	5.4	12	1.1	4.3
55–59	61	2.5	7.4	31	2.4	7.8	30	2.7	7.0
60–64	110	4.6	12.0	69	5.3	13.1	41	3.7	10.7
65–69	217	9.0	21.0	142	11.0	24.1	75	6.8	17.5
70–74	337	14.0	35.1	200	15.5	39.6	137	12.3	29.8
75–79	481	20.0	55.1	266	20.6	60.2	215	19.4	49.1
80–84	461	19.2	74.3	256	19.8	80.0	205	18.5	67.6
85+	619	25.7	100.0	259	20.0	100.0	360	32.4	100.0
All ages	2404	100.0		1293	100.0		1111	100.0	

Table 5

Age-specific incidence and DCO rate
for period 2007–2020

Age at diagnosis Years	Males n	Females n	Males Age- spec. incid.	Females Age- spec. incid.	Males DCO rate n=554 %	Females DCO rate n=592 %
0– 4	5	2	0.3	0.1		
5– 9	4	2	0.3	0.1		
10–14	12	8	0.8	0.5		
15–19	5	2	0.3	0.1		
20–24						
25–29	2	4	0.1	0.2		
30–34	3		0.1			
35–39	2	7	0.1	0.3		14.3
40–44	9	5	0.4	0.2		
45–49	14	6	0.5	0.2		
50–54	14	12	0.5	0.5	7.1	8.3
55–59	31	30	1.5	1.4	19.4	13.3
60–64	69	41	3.9	2.2	26.1	19.5
65–69	141	75	8.6	4.1	31.9	24.0
70–74	200	137	13.3	8.0	24.5	29.9
75–79	266	215	22.0	14.3	33.8	44.2
80–84	255	204	35.2	19.2	55.3	63.2
85+	259	360	55.5	34.5	78.8	81.9
All ages	1291	1110			42.9	53.3
Incidence						
Raw			4.0	3.3		
WS			1.7	1.0		
ES			2.6	1.6		
BRD–S			3.7	2.2		

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).




Figure 6. Age distribution (males: mean=75.3 yrs, median=77.8 yrs; females: mean=78.2 yrs, median=80.4 yrs) and age-specific incidence.




Figure 6a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:
 Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 21 Regs Research Data, released April 2021, based on the November 2020 submission. <http://www.seer.cancer.gov>.

Table 7a

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of further malignancies
for period 1998–2020

MALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C03–C06 Oral cavity	1	0.3	3.2	0.1	17.9	2.7	
C12–C13 Hypopharynx	1	0.2	4.9	0.1	27.5	3.1	100.0
C15 Oesophagus	3	0.9	3.4	0.7	10.0	8.3	
C16 Stomach	5	2.0	2.5	0.8	5.9	11.8	20.0
C17 Small intestine	2	0.3	7.0	0.8	25.2	6.7	
C18 Colon	9	4.9	1.9	0.8	3.5	16.1	11.1
C19–C20 Rectum	7	2.4	2.9	1.2	6.0 #	17.9	
C21 Anus/canal	1	0.1	9.4	0.2	52.1	3.5	
C22 Liver	6	1.4	4.3	1.6	9.4 #	18.0	16.7
C25 Pancreas	3	2.0	1.5	0.3	4.4	4.0	
C32 Larynx	3	0.4	7.3	1.5	21.3 #	10.1	
C33–C34 Lung	24	5.5	4.4	2.8	6.5 #	72.2	20.8
C38,C45 Mesothelioma	1	0.4	2.8	0.1	15.8	2.5	
C43 Malign. melanoma	2	2.1	0.9	0.1	3.4	-0.5	
C61 Prostate	18	13.3	1.4	0.8	2.1	18.3	11.1
C64 Kidney	4	1.6	2.6	0.7	6.6	9.5	
C67 Bladder	7	2.5	2.8	1.1	5.8 #	17.6	28.6
C70–C72 CNS cancer	1	0.6	1.8	0.0	9.8	1.7	
C76–C79 CUP	4	0.8	4.8	1.3	12.2 #	12.4	25.0
C81 Hodgkin lymphoma	1	0.1	9.8	0.2	54.8	3.5	
C82–C85 NHL	24	2.1	11.5	7.4	17.1 #	85.6	8.3
C90 Mult. myeloma	11	0.7	16.7	8.3	29.9 #	40.4	
C91–C96 Leukaemia	143	0.8	180.3	151.9	212.4 #	555.1	18.9
Not observed	0	2.9	0.0	0.0	1.3	-11.4	
All further malignancies	281	48.1	5.8	5.2	6.6 #	909.0	15.3
Patients		1148					
Median age at next malignancy (years)		75.9					
Person-years		2562					
Mean observation time (years)		2.2					
Median observation time (years)		1.1					

The occurrence of further specified malignancy is statistically significant.

Table 7b


Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of further malignancies
for period 1998–2020

FEMALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C00 Lip	1	0.0	44.8	1.1	249.7 #	4.6	
C15 Oesophagus	2	0.2	11.4	1.4	41.1 #	8.6	
C16 Stomach	2	1.0	2.0	0.2	7.3	4.8	
C18 Colon	5	2.8	1.8	0.6	4.2	10.4	20.0
C19–C20 Rectum	2	1.1	1.9	0.2	6.7	4.4	
C22 Liver	1	0.4	2.8	0.1	15.5	3.0	
C25 Pancreas	3	1.4	2.2	0.4	6.3	7.6	33.3
C26 GI cancer	1	0.1	17.6	0.4	98.3	4.5	
C33–C34 Lung	3	2.0	1.5	0.3	4.4	4.9	33.3
C37 Thymus	1	0.0	68.8	1.7	383.2 #	4.7	
C50 Breast	17	7.5	2.3	1.3	3.6 #	45.0	23.5
C51 Vulva	1	0.3	3.2	0.1	18.0	3.3	
C53 Cervix uteri	1	0.3	3.5	0.1	19.6	3.4	
C56 Ovary	1	1.0	1.0	0.0	5.3	-0.2	100.0
C67 Bladder	3	0.6	5.1	1.0	14.8 #	11.4	33.3
C73 Thyroid	1	0.3	3.1	0.1	17.4	3.2	
C76–C79 CUP	2	0.5	3.7	0.4	13.3	6.9	
C82–C85 NHL	9	1.1	8.3	3.8	15.7 #	37.5	
C90 Mult. myeloma	9	0.3	26.0	11.9	49.3 #	41.0	
C91–C96 Leukaemia	113	0.4	268.3	221.2	322.6 #	533.2	16.8
Not observed	0	5.3	0.0	0.0	0.7 #	-25.1	
All further malignancies	178	26.6	6.7	5.7	7.7 #	717.0	15.7
Patients		878					
Median age at next malignancy (years)		76.7					
Person-years		2111					
Mean observation time (years)		2.4					
Median observation time (years)		1.1					

The occurrence of further specified malignancy is statistically significant.

Average incidence (Germany 1987 standard population) 2007 - 2020: Males



Average incidence (Germany 1987 standard population) 2007 - 2020: Females





Figure 8a. Map of cancer incidence (german standard population, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual incidence rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 3.7/100,000 WS N=1,291, females 2.2/100,000 WS N=1,110).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,727 female residents (averaged) in the period from 2007 to 2020 a total of 25 women were identified with newly diagnosed myelodysplastic syndrome. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 2.0/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 1.1 and 3.4/100,000.

Standardized incidence ratio (SIR) 2007 - 2020: Males



Standardized incidence ratio (SIR) 2007 - 2020: Females




Figure 8b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual SIR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=1,291, females N=1,110).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2020 a total of 25 women were identified with newly diagnosed myelodysplastic syndrome. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.85. Though, the value of this parameter may vary with an underlying probability of 99% between 0.48 and 1.40, and is therefore not statistically striking.

MORTALITY

Table 9a

Annual cohorts: Incident cancers, follow-up status, proportion of DCO, deaths among the annual cohorts and proportion of available death certificates (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	51	100.0	52.9	49	96.1	98.0
1999	57	100.0	47.4	55	96.5	98.2
2000	68	100.0	60.3	65	95.6	100.0
2001	60	100.0	61.7	57	95.0	98.2
2002	110	100.0	54.5	107	97.3	99.1
2003	99	99.0	56.6	95	96.0	96.8
2004	111	99.1	61.3	104	93.7	98.1
2005	143	98.6	65.7	138	96.5	97.8
2006	150	96.0	56.0	135	90.0	99.3
2007	195	96.4	50.3	174	89.2	97.7
2008	205	98.5	47.8	188	91.7	100.0
2009	203	100.0	40.9	175	86.2	98.3
2010	206	99.5	44.2	184	89.3	99.5
2011	246	100.0	44.7	223	90.7	98.7
2012	211	99.5	51.2	194	91.9	99.5
2013	221	100.0	41.6	191	86.4	98.4
2014	175	98.9	53.7	164	93.7	95.7
2015	179	99.4	55.9	163	91.1	97.5
2016	198	99.0	59.6	174	87.9	94.8
2017	169	99.4	58.6	144	85.2	93.1
2018	111	99.1	45.9	83	74.8	84.3
2019	45	100.0	4.4	27	60.0	88.9
2020	40	100.0	7.5	21	52.5	95.2
1998-2020	3253	99.1	50.4	2910	89.5	97.4

Table 9b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased within the same year of being diagnosed with cancer (incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	51	37	100.0	27	52.9
1999	57	52	98.1	35	61.4
2000	68	60	100.0	43	63.2
2001	60	41	100.0	31	51.7
2002	110	62	100.0	58	52.7
2003	99	72	98.6	56	56.6
2004	111	74	97.3	68	61.3
2005	143	89	96.6	93	65.0
2006	150	104	99.0	88	58.7
2007	195	108	99.1	98	50.3
2008	205	120	98.3	108	52.7
2009	203	122	99.2	89	43.8
2010	206	120	99.2	100	48.5
2011	246	139	98.6	121	49.2
2012	211	138	98.6	113	53.6
2013	221	129	100.0	100	45.2
2014	175	143	99.3	97	55.4
2015	179	157	100.0	110	61.5
2016	198	155	100.0	126	63.6
2017	169	132	100.0	110	65.1
2018	111	114	79.8	57	51.4
2019	45	51	47.1	9	20.0
2020	40	70	95.7	12	30.0
1998–2020	3253	2289	96.9	1749	53.8

Table 9c

Annual cohorts of deaths, proportion of cancer-related and non-cancer-related deaths, and cancer recorded on death certificates
(incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,
and from 4.10 to 4.94 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer- related %	Prop. non-cancer- related %	Prop. cancer recorded on death certificate %
1998	37	48.6	51.4	97.3
1999	52	57.7	42.3	96.1
2000	60	65.0	35.0	96.7
2001	41	41.5	58.5	100.0
2002	62	72.6	27.4	98.4
2003	72	68.1	31.9	94.4
2004	74	64.9	35.1	100.0
2005	89	66.3	33.7	94.2
2006	104	73.1	26.9	97.1
2007	108	74.1	25.9	97.2
2008	120	73.3	26.7	96.6
2009	122	77.0	23.0	91.7
2010	120	72.5	27.5	91.6
2011	139	78.4	21.6	96.4
2012	138	78.3	21.7	94.1
2013	129	81.4	18.6	94.6
2014	143	68.5	31.5	87.3
2015	157	73.2	26.8	91.1
2016	155	72.9	27.1	91.6
2017	132	68.2	31.8	86.4
2018	114	61.4	38.6	78.0
2019	51	33.3	66.7	75.0
2020	70	45.7	54.3	67.2
1998–2020	2289	69.3	30.7	92.1

Table 10a

Medians of age at death according to the grouping in Table 9
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	13	73.0	72.3	73.9	73.0
1999	26	81.1	77.6	85.2	80.9
2000	28	74.7	75.3	74.2	75.3
2001	18	78.9	75.4	81.7	78.9
2002	33	78.8	78.8	79.7	78.8
2003	39	77.4	77.2	81.6	77.3
2004	35	80.7	79.9	83.3	80.7
2005	41	77.9	76.5	79.8	78.2
2006	64	76.1	74.5	80.1	76.3
2007	59	78.5	79.3	77.5	79.0
2008	72	76.0	73.2	80.8	76.0
2009	59	76.7	76.7	77.2	77.4
2010	71	81.2	79.3	85.6	80.7
2011	69	77.8	77.8	78.1	77.8
2012	78	78.2	78.1	80.8	78.2
2013	73	79.4	79.0	82.1	78.8
2014	71	79.4	79.7	79.3	80.7
2015	81	78.1	76.7	83.1	78.2
2016	88	80.6	77.8	85.7	79.8
2017	74	79.6	79.3	80.7	79.6
2018	66	79.7	79.6	79.9	80.1
2019	32	81.0	76.7	82.3	79.9
2020	35	81.3	76.7	82.1	78.3
1998–2020	1225	78.7	77.3	81.2	78.5

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 10b

Medians of age at death according to the grouping in Table 9
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	24	83.2	76.7	86.7	82.0
1999	26	84.9	84.2	85.6	84.4
2000	32	82.1	78.2	83.8	82.0
2001	23	84.9	81.0	88.2	84.9
2002	29	81.4	85.2	80.9	82.9
2003	33	84.5	82.2	84.8	84.5
2004	39	83.4	80.1	86.7	83.4
2005	48	83.6	81.5	85.8	83.7
2006	40	83.8	83.9	81.9	83.7
2007	49	84.2	83.7	85.6	84.2
2008	48	82.0	81.1	84.6	82.0
2009	63	78.5	78.5	80.3	80.7
2010	49	80.9	81.1	78.8	81.1
2011	70	82.1	81.0	83.3	82.6
2012	60	80.1	77.3	85.1	79.7
2013	56	80.3	81.3	78.7	81.3
2014	72	81.4	79.5	83.5	81.2
2015	76	80.8	79.0	86.6	80.8
2016	67	80.9	79.9	81.1	80.1
2017	58	82.6	82.6	82.6	82.6
2018	48	79.9	81.6	78.9	81.7
2019	19	79.1	79.7	78.6	79.7
2020	35	81.8	79.3	82.5	76.7
1998–2020	1064	81.7	80.9	83.5	82.0

By 2018, Bavarians' life expectancy at birth is estimated at 79.3 years for boys and 83.8 years for girls.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11a

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death

MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	6	0.5	0.35	0.3	0.26	0.5	0.32	0.6	0.33
1999	14	1.3	0.48	0.8	0.47	1.2	0.49	1.8	0.47
2000	19	1.7	0.51	0.9	0.47	1.5	0.50	2.1	0.52
2001	6	0.5	0.29	0.3	0.29	0.4	0.29	0.7	0.29
2002	20	1.1	0.33	0.5	0.32	0.9	0.34	1.4	0.34
2003	29	1.5	0.57	0.7	0.53	1.2	0.56	2.0	0.62
2004	25	1.3	0.38	0.6	0.32	1.0	0.35	1.7	0.42
2005	27	1.4	0.39	0.6	0.39	1.1	0.39	1.6	0.38
2006	47	2.5	0.54	1.1	0.48	1.8	0.50	2.6	0.54
2007	46	2.1	0.43	0.9	0.36	1.5	0.40	2.2	0.43
2008	54	2.4	0.58	1.1	0.56	1.7	0.57	2.4	0.56
2009	47	2.1	0.45	0.9	0.39	1.5	0.43	2.2	0.46
2010	50	2.2	0.43	0.9	0.41	1.5	0.43	2.2	0.42
2011	55	2.5	0.46	1.0	0.45	1.6	0.47	2.4	0.48
2012	64	2.8	0.58	1.2	0.52	1.9	0.56	2.7	0.57
2013	59	2.6	0.48	1.0	0.43	1.6	0.47	2.4	0.47
2014	49	2.1	0.51	0.7	0.42	1.3	0.47	1.9	0.50
2015	61	2.6	0.70	0.9	0.63	1.6	0.66	2.3	0.69
2016	66	2.7	0.57	1.0	0.65	1.7	0.60	2.5	0.58
2017	53	2.2	0.53	0.8	0.50	1.3	0.51	1.9	0.53
2018	41	1.7	0.60	0.6	0.59	0.9	0.57	1.4	0.60
2019	11	0.5	0.44	0.2	0.46	0.3	0.44	0.4	0.44
2020	16	0.7	0.64	0.3	0.59	0.4	0.62	0.6	0.62
1998-2020	865	1.9	0.50	0.8	0.46	1.3	0.48	1.9	0.50

Table 11b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death

FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	12	1.0	0.35	0.4	0.40	0.6	0.38	0.9	0.37
1999	16	1.3	0.57	0.4	0.59	0.7	0.58	1.0	0.57
2000	20	1.7	0.65	0.6	0.73	0.9	0.69	1.2	0.64
2001	11	0.9	0.28	0.3	0.25	0.5	0.27	0.7	0.30
2002	25	1.3	0.51	0.3	0.43	0.6	0.46	0.9	0.46
2003	20	1.0	0.42	0.3	0.37	0.5	0.40	0.7	0.41
2004	23	1.2	0.51	0.4	0.59	0.6	0.54	0.9	0.52
2005	32	1.6	0.44	0.4	0.38	0.7	0.42	1.1	0.45
2006	29	1.4	0.46	0.4	0.40	0.7	0.43	1.0	0.44
2007	34	1.5	0.39	0.4	0.30	0.7	0.34	1.0	0.36
2008	34	1.5	0.30	0.4	0.22	0.7	0.26	1.0	0.28
2009	47	2.0	0.48	0.6	0.43	1.0	0.44	1.5	0.46
2010	37	1.6	0.41	0.5	0.42	0.8	0.42	1.1	0.43
2011	54	2.3	0.43	0.6	0.37	1.0	0.40	1.5	0.41
2012	44	1.9	0.44	0.5	0.38	0.9	0.43	1.3	0.45
2013	46	1.9	0.47	0.6	0.47	1.0	0.47	1.3	0.47
2014	49	2.0	0.63	0.6	0.66	0.9	0.66	1.4	0.67
2015	54	2.2	0.59	0.7	0.72	1.1	0.64	1.5	0.63
2016	47	1.9	0.57	0.5	0.59	0.8	0.59	1.2	0.55
2017	37	1.5	0.54	0.4	0.49	0.6	0.51	0.9	0.52
2018	29	1.2	0.67	0.3	0.74	0.5	0.72	0.8	0.71
2019	6	0.2	0.30	0.1	0.18	0.1	0.23	0.2	0.27
2020	16	0.6	1.07	0.1	0.76	0.2	0.85	0.4	0.99
1998-2020	722	1.5	0.48	0.4	0.44	0.7	0.46	1.0	0.47

Table 12

Age distribution of age at death (cancer-related) for period 2007-2020
(incl. multiple malignancies)

Age at death Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9	1	0.1	0.1	1	0.1	0.1			0.0
10-14	1	0.1	0.2			0.1	1	0.2	0.2
15-19	2	0.2	0.3	1	0.1	0.3	1	0.2	0.4
20-24	0	0.0	0.3			0.3			0.4
25-29	0	0.0	0.3			0.3			0.4
30-34	0	0.0	0.3			0.3			0.4
35-39	3	0.2	0.6	2	0.3	0.6	1	0.2	0.6
40-44	4	0.3	0.9	1	0.1	0.7	3	0.6	1.1
45-49	10	0.8	1.7	6	0.9	1.6	4	0.7	1.9
50-54	9	0.7	2.5	4	0.6	2.2	5	0.9	2.8
55-59	22	1.8	4.3	12	1.8	4.0	10	1.9	4.7
60-64	62	5.1	9.5	42	6.3	10.3	20	3.7	8.4
65-69	109	9.0	18.5	73	10.9	21.1	36	6.7	15.2
70-74	193	16.0	34.5	115	17.1	38.2	78	14.6	29.8
75-79	232	19.2	53.7	133	19.8	58.0	99	18.5	48.3
80-84	259	21.5	75.2	148	22.0	80.1	111	20.8	69.1
85+	299	24.8	100.0	134	19.9	100.0	165	30.9	100.0
All ages	1206	100.0		672	100.0		534	100.0	

Table 13

Age-specific mortality (cancer-related) and proportion of all cancers
for period 2007-2020
(incl. multiple malignancies)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index
0- 4						
5- 9	1		0.1	0.25		
10-14		1			0.1	0.13
15-19	1	1	0.1	0.20	0.1	0.50
20-24						
25-29						
30-34						
35-39	2	1	0.1	1.00	0.0	0.14
40-44	1	3	0.0	0.11	0.1	0.60
45-49	6	4	0.2	0.43	0.2	0.67
50-54	4	5	0.2	0.29	0.2	0.42
55-59	12	10	0.6	0.39	0.5	0.33
60-64	42	20	2.4	0.61	1.1	0.49
65-69	73	36	4.5	0.52	2.0	0.48
70-74	115	78	7.7	0.58	4.5	0.57
75-79	133	99	11.0	0.50	6.6	0.46
80-84	148	111	20.4	0.58	10.4	0.54
85+	134	165	28.7	0.52	15.8	0.46
All ages	672	534				
Mortality						
Raw			2.1	0.52	1.6	0.48
WS			0.8	0.48	0.4	0.45
ES			1.3	0.50	0.7	0.46
BRD-S			1.9	0.52	1.1	0.48
PYLL-70						
per 100,000			3.7		2.7	
ES			3.3		2.4	
AYLL-70			7.5		9.5	

Table 14a

Further malignancies in deaths in period 1998–2020
MALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
	1	0.2	1	100.0				
C00 Lip	1	0.2	1	100.0				
C03–C06 Oral cavity	3	0.6	2	66.7			1	33.3
C07–C08 Salivary gland	1	0.2	1	100.0				
C09–C10 Oropharynx	2	0.4	2	100.0				
C15 Oesophagus	5	1.0	2	40.0	1	20.0	2	40.0
C16 Stomach	14	2.7	10	71.4			4	28.6
C17 Small intestine	1	0.2					1	100.0
C18 Colon	32	6.2	23	71.9	2	6.3	7	21.9
C19–C20 Rectum	16	3.1	9	56.3	2	12.5	5	31.3
C21 Anus/canal	2	0.4	2	100.0				
C22 Liver	4	0.8	1	25.0	1	25.0	2	50.0
C25 Pancreas	4	0.8	2	50.0	1	25.0	1	25.0
C32 Larynx	6	1.2	4	66.7			2	33.3
C33–C34 Lung	28	5.4	5	17.9	8	28.6	15	53.6
C38,C45 Mesothelioma	1	0.2					1	100.0
C43 Malign. melanoma	14	2.7	13	92.9			1	7.1
C44 Skin others	35	6.8	21	60.0	1	2.9	13	37.1
C50 Breast	1	0.2	1	100.0				
C60 Penis	1	0.2	1	100.0				
C61 Prostate	79	15.3	67	84.8	5	6.3	7	8.9
C62 Testis	1	0.2	1	100.0				
C64 Kidney	5	1.0	5	100.0				
C65 Renal pelvis	2	0.4	2	100.0				
C66 Ureter	2	0.4	2	100.0				
C67 Bladder	19	3.7	15	78.9			4	21.1
C69 Eye melanoma	2	0.4	2	100.0				
C70–C72 CNS cancer	4	0.8	3	75.0	1	25.0		
C73 Thyroid	4	0.8	4	100.0				
C74–C80 Cancer others	1	0.2			1	100.0		
C76–C79 CUP	4	0.8			1	25.0	3	75.0
C81 Hodgkin lymphoma	2	0.4	1	50.0			1	50.0
C82–C85 NHL	45	8.7	26	57.8	11	24.4	8	17.8
C90 Mult. myeloma	12	2.3	8	66.7	2	16.7	2	16.7
C91–C96 Leukaemia	161	31.3			54	33.5	107	66.5
All further malignancies	515	100.0	237	46.0	91	17.7	187	36.3

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 14b

Further malignancies in deaths in period 1998-2020
FEMALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C00 Lip	1	0.3					1	100.0
C03-C06 Oral cavity	2	0.6	1	50.0			1	50.0
C09-C10 Oropharynx	1	0.3	1	100.0				
C15 Oesophagus	1	0.3					1	100.0
C16 Stomach	2	0.6	1	50.0			1	50.0
C17 Small intestine	1	0.3	1	100.0				
C18 Colon	19	5.3	16	84.2			3	15.8
C19-C20 Rectum	4	1.1	2	50.0	1	25.0	1	25.0
C21 Anus/canal	3	0.8	3	100.0				
C22 Liver	1	0.3			1	100.0		
C23-C24 Bile	1	0.3	1	100.0				
C25 Pancreas	3	0.8			1	33.3	2	66.7
C26 GI cancer	1	0.3					1	100.0
C33-C34 Lung	14	3.9	7	50.0	5	35.7	2	14.3
C37 Thymus	1	0.3			1	100.0		
C43 Malign. melanoma	5	1.4	5	100.0				
C44 Skin others	19	5.3	12	63.2	1	5.3	6	31.6
C46,C49 Soft tissue	2	0.6	1	50.0			1	50.0
C48 Peritoneal	1	0.3	1	100.0				
C50 Breast	70	19.4	55	78.6	5	7.1	10	14.3
C51 Vulva	3	0.8	3	100.0				
C53 Cervix uteri	4	1.1	3	75.0			1	25.0
C54 Corpus uteri	17	4.7	17	100.0				
C56 Ovary	5	1.4	5	100.0				
C57.9 Fem. urogen.	1	0.3	1	100.0				
C64 Kidney	7	1.9	7	100.0				
C66 Ureter	1	0.3	1	100.0				
C67 Bladder	3	0.8	2	66.7	1	33.3		
C68 Urinary org.	1	0.3			1	100.0		
C69 Eye lymphoma	1	0.3	1	100.0				
C70-C72 CNS cancer	1	0.3			1	100.0		
C73 Thyroid	7	1.9	6	85.7			1	14.3
C81 Hodgkin lymphoma	1	0.3	1	100.0				
C82-C85 NHL	17	4.7	10	58.8	6	35.3	1	5.9
C90 Mult. myeloma	5	1.4	1	20.0	2	40.0	2	40.0
C91-C96 Leukaemia	134	37.2			42	31.3	92	68.7
All further malignancies	360	100.0	165	45.8	68	18.9	127	35.3

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 15

Age-specific mortality (cancer-related) and proportion of all cancers
for period 2007-2020
(First primaries only *)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index
0- 4						
5- 9	1		0.1	0.25		
10-14		1			0.1	0.13
15-19	1		0.1	0.20		
20-24						
25-29						
30-34						
35-39	2	1	0.1	1.00	0.0	0.20
40-44	1	2	0.0	0.13	0.1	0.50
45-49	5	2	0.2	0.38	0.1	0.40
50-54	4	3	0.2	0.31	0.1	0.50
55-59	10	5	0.5	0.45	0.2	0.24
60-64	33	15	1.9	0.60	0.8	0.56
65-69	47	23	2.9	0.51	1.3	0.49
70-74	72	52	4.8	0.57	3.0	0.63
75-79	82	62	6.8	0.52	4.1	0.42
80-84	75	80	10.4	0.60	7.5	0.58
85+	83	125	17.8	0.53	12.0	0.45
All ages	416	371				
Mortality						
Raw			1.3	0.52	1.1	0.48
WS			0.5	0.46	0.3	0.44
ES			0.8	0.50	0.5	0.46
BRD-S			1.2	0.52	0.7	0.48
PYLL-70						
per 100,000			3.1		1.7	
ES			2.8		1.5	
AYLL-70			8.5		9.1	

* See corresponding tables with multiple malignancies.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers
for period 2007-2020
(**Single primaries only ***)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index
0- 4						
5- 9	1		0.1	0.25		
10-14		1			0.1	0.13
15-19	1		0.1	0.20		
20-24						
25-29						
30-34						
35-39	1	1	0.0	0.50	0.0	0.25
40-44	1		0.0	0.14		
45-49	3		0.1	0.30		
50-54	1	2	0.0	0.14	0.1	0.50
55-59	7	3	0.3	0.39	0.1	0.20
60-64	25	12	1.4	0.57	0.6	0.55
65-69	32	15	2.0	0.54	0.8	0.45
70-74	44	29	2.9	0.48	1.7	0.46
75-79	53	46	4.4	0.41	3.1	0.38
80-84	62	65	8.6	0.57	6.1	0.53
85+	65	110	13.9	0.45	10.6	0.41
All ages	296	284				
Mortality						
Raw			0.9	0.46	0.8	0.42
WS			0.4	0.40	0.2	0.38
ES			0.6	0.44	0.4	0.40
BRD-S			0.8	0.46	0.5	0.42
PYLL-70 per 100,000			2.1		1.0	
ES			2.0		1.0	
AYLL-70			8.5		8.5	

* See corresponding tables with multiple malignancies.





Figure 17. Distribution of age at death (bars; males: mean=75.0 yrs, median=75.8 yrs; females: mean=77.2 yrs, median=78.8 yrs) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at myelodysplastic syndrome-related death (see Table 10) should be considered.

Average mortality (Germany 1987 standard population) 2007 - 2020: Males



Average mortality (Germany 1987 standard population) 2007 - 2020: Females





Figure 18a. Map of cancer mortality (german standard population) by county averaged for period 2007 to 2020. According to their individual mortality rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 1.9/100,000 WS N=672, females 1.1/100,000 WS N=534).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,727 female residents (averaged) in the period from 2007 to 2020 a total of 13 women died from myelodysplastic syndrome. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 1.1/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.4 and 2.1/100,000.

Standardized mortality ratio (SMR) 2007 - 2020: Males



Standardized mortality ratio (SMR) 2007 - 2020: Females




Figure 18b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual SMR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=672, females N=534).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2020 a total of 13 women died from myelodysplastic syndrome. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.92. Though, the value of this parameter may vary with an underlying probability of 99% between 0.40 and 1.81, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases, where applicable. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head&neck and lung).

The ratio of mortality and incidence (mortality-to-incidence ratio, **MIR, MI-Index**) is a statistical index that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MIR. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

MCR	Munich Cancer Registry (Tumorregister München)
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
SEER	Surveillance, Epidemiology, and End Results (USA)
DCO	Death certificate only
BRD-S	German (FRG) standard population
ES	European standard population (old)
WS	World standard population
SIR	Standardized incidence ratio
CI	Confidence interval
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
SMR	Standardized mortality ratio
MI-index	Ratio of mortality to incidence, MIR
FRG	Federal Republic of Germany

Recommended Citation

Munich Cancer Registry. ICD-10 D46: Myelodysplastic syndrome - Incidence and Mortality [Internet]. 2021 [updated 2021 Dec 21; cited 2022 Feb 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/base/bD46__E-ICD-10-D46-Myelodysplastic-syndrome-incidence-and-mortality.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.